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Abstract. – OBJECTIVE: Coronavirus dis-
ease 2019 (COVID-19) is an emerging infec-
tious disease that was first reported in Wuhan, 
China, and has subsequently spread world-
wide. An association between increased ve-
nous thromboembolism in patients with pneu-
monia-related to COVID-19 has not yet been 
well described.
PATIENTS AND METHODS: We aimed to il-
lustrate cases of pulmonary thromboembolism 
in patients with acute respiratory distress syn-
drome related to COVID-19 treated in our inten-
sive care unit. The medical records of patients 
affected by COVID-19 with acute respiratory dis-
tress syndrome in our institute from 1/3/2020 to 
31/3/2020 were retrospectively reviewed. 
RESULTS: Our center registered a high prev-
alence of thromboembolic events among 62 pa-
tients affected by acute respiratory distress 
syndrome related to COVID-19 despite a regular 
antithrombotic prophylaxis. Out of these, 32 pa-
tients were transferred to other hospitals, and 
30 were treated in our center. Venous thrombo-
embolism was registered in 12 (19.3%) cases. In 
particular, 11 diagnoses of pulmonary embolism 
and 1 diagnosis of deep vein thrombosis were 
formulated. We described a case series of ve-
nous thromboembolism in nine patients treated 
in our Intensive Care Unit (ICU). Main pulmonary 
arteries were always involved in these patients. 
None of them died.
CONCLUSIONS: In conclusion, critically ill pa-
tients with ARDS related to COVID-19 may have 
an increased risk of VTE that could be a leading 
cause of mortality. These patients require a high 
index of clinical suspicion and an accurate diag-
nostic approach, in order to immediately start 
an appropriate anticoagulant treatment.
Key Words:
COVID-19, Acute Respiratory Distress Syndrome, 
Pulmonary embolism, Deep vein thrombosis.
Introduction
Coronavirus disease 2019 (COVID-19) was first 
described in Wuhan, China, and has subsequently 
spread worldwide1. Its outcome seems to be deter-
mined by the extent of the host immune system 
imbalance. The primary immune response usually 
leads to viral clearance. However, for unclear rea-
sons, the secondary immune response may be ex-
aggerated and, in some cases, may lead to multiple 
organ failure, acute respiratory distress syndrome 
(ARDS) and death2. This exaggerated response is 
known as cytokine release syndrome (CRS), and 
it has an important role in the activation of co-
agulation. Clinical observations have shown that 
patients with severe COVID-19 pneumonia have 
coagulation dysfunction3,4.
In recent studies, thromboembolic events were 
registered in patients with COVID-19 pneumonia5-7. 
We retrospectively described cases of venous 
thromboembolism (VTE) in patients with ARDS 
related to COVID-19 that have been treated in our 
intensive care unit (ICU). 
Patients and Methods
 
We retrospectively reviewed the medical re-
cords of patients affected by ARDS related to 
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COVID-19 in our ICU from 1/3/2020 to 31/3/2020. 
COVID-19 diagnosis was made by clinical fea-
tures and nose swab positivity. ARDS diagnosis 
followed the Berlin definition criteria8. All pa-
tients admitted to our ICU were intubated and 
mechanically ventilated. After the stabilization 
of clinical parameters, some patients were trans-
ferred to other hospitals due to the overwhelming 
inflow of COVID-19 patients. Information about 
the outcome of transferred patients was obtained 
by interview over the phone. All patients treated 
in our center were handled in accordance with 
guidelines on the management of critically ill 
adults with COVID-199. All described patients 
received antithrombotic prophylaxis with Enox-
aparin 100 U/kg/24h. Patients more than 80 kg 
received Enoxaparin 5000 U twice a day. Specif-
ic antiviral therapy includes Lopinavir/Ritonavir 
and hydroxychloroquine. In case of clinical signs 
of bacterial coinfection confirmed by procalci-
tonin elevation and/or cultural positivity, antibi-
otic therapy was introduced.
Results 
Alessandria hospital ICU admitted 62 patients 
with diagnosis of ARDS related to COVID-19. In 
this population, 12 VTE were registered (19.3%), 
in particular, 11 diagnoses of pulmonary embo-
lism (PE) and one of deep vein thrombosis (DVT) 
were made (Figure 1). Only 25% of patients com-
plicated by thromboembolism were represented 
by females and patients’ median age was 53 (50-
59) years old.
Among 62 patients, 32 patients were trans-
ferred to other hospitals and 30 were treated in 
our center. Nine of reported diagnosis of VTE 
were made in our ICU; thus, the prevalence of 
VTE registered in our center is 30%. Thrombotic 
events took place on average after 64-9 days after 
ICU admission and 1411-15 days after symptoms 
onset. Demographic data and disease severity are 
shown in Table I. Principal clinical parameters 
registered the day when VTE was diagnosed are 
summarized in Table II and patients’ laboratory 
test results are described in Table III. 
Only two patients (Patient 1 and Patient 3) 
with PE registered important hemodynamic in-
stability which led to the diagnosis. In other 
cases, the clinical suspicion stemmed from alter-
ation of gaseous exchanges and/or hemodynamic 
values not fully explained by the clinical picture. 
In the vast majority of patients, D-Dimer values 
were increased the day of diagnosis. However, 
only in five cases these values were markedly 
altered (Table III). In all patients with PE main 
pulmonary arteries were involved (Table II). In 
Figure 2, computed tomography scan imaging of 
ARDS and pulmonary emboli related to patient 
1 are shown. DVT was associated to PE in three 
cases and in one case it is the only VTE finding. 
All of these patients were treated with the load 
and subsequent continuous infusion of Heparin. 
In addition, in patient 3, thromboendoarterecto-
my was performed directly in ICU and in patient 
1 i.v. thrombolytic therapy was administered. 
None of the described patients died.
Discussion 
A correlation between increased VTE events 
and ARDS related to COVID-19 was observed. 
Out of these 62 patients 19.3% had a thrombo-
embolic complication. Several factors contribute 
to the increase of VTE risk in ICU patients. Rec-
ognized risk factors for DVT are related to one 
or more elements of Virchow’s triad: flow stasis, 
vessel injury and hypercoagulability. Flow sta-
sis, due to prolonged immobility, mechanical 
ventilation, use of sedatives and neuromuscular 
block plays a major role in ICU patients10-12. 
Moreover, in this population, vessel injury may 
be due to catheter insertion in central veins and 
hypercoagulability may be induced by sepsis or 
Figure 1. Algorithm of thromboembolic complication 
distribution in intubated patients with moderate or severe 
ARDS related to Covid-19. All pulmonary embolism di-
agnoses were confirmed by CT angiography except one, 
that was confirmed by transesophageal ultrasound due to 
patients’ very high hemodynamic instability. Legend: PE, 
pulmonary embolism; DVT, deep vein thrombosis.
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dehydration10,11. Under such pathophysiological 
conditions, the occurrence of additional DVT 
risk factors related to COVID-19 can precipitate 
thrombosis. The impact of COVID-19 on blood 
clotting has not yet been completely investi-
gated. However, we know that CRS is thought 
to play an important role in disease severity13. 
CRS is associated with increased levels of in-
flammatory cytokines and activation of T lym-
phocytes, macrophages, and endothelial cells. 
In particular, interleukin 6 and tumor necrosis 
factor seems to hold a key role leading to vas-
cular leakage and to activation of complement, 
tissue factor and coagulation cascade14,15. Thus, 
the high prevalence of the thrombotic events 
in patients with ARDS by COVID-19 may be 
induced by cross-talking between immune and 
coagulation systems.
PE is stratified into massive, sub-massive, and 
low-risk based upon the presence or absence of 
hypotension and right ventricular dysfunction 
or dilation. This stratification is associated with 
mortality risk16. However, many patients, includ-
ing those with large PE, have mild symptoms or 
are asymptomatic17. This nonspecific presenta-
tion may be magnified in patients mechanically 
ventilated with ARDS COVID-19 related. This 
is due to an overlap between PE manifestations 
and COVID-19 ARDS clinical signs. In fact, 
alteration of arterial blood gases, D-dimer lev-
els, and echocardiography are neither sensitive 
nor specific as diagnostic of suspected PE in 
this situation. All our patient at ICU admission 
had severe or moderate ARDS and increased of 
D-dimer values. Only in five cases, D-Dimer 
was markedly increased on the day of diagnosis. 
All patient on the day of diagnosis were deeply 
sedated and treated with high PEEP and aminic 
support before PE suspect. Only patient 1 and 
patient 3 registered severe hemodynamic insta-
bility and deterioration of respiratory function 
due to PE (Table II). Instead, Patient 2 registered 
moderate hemodynamic instability with difficult 
control of blood pressure without impact on gas 
exchange. Those three cases of PE stemmed a 
clinical suspicion of VTE in other COVID-19 
patients. Thus, even if other patients registered 
only minor alteration of gaseous exchanges and/
or hemodynamic alterations, PE diagnosis was 
made. Moreover, considering other VTE risk 
factors of our patients, Table I shows that only 
two subjects were obese and only one patient 
had a history of cancer. 
Our experience emphasizes that identifying a 
PE in patients with COVID-19 ARDS is really 
challenging. On the other hand, a delay in diag-
nosis of PE is associated with a poor outcome18. 
As a consequence, these patients require a high 
Table I. Demographic and clinical history of patients at ICU admission who subsequently developed thromboembolic events. 
       Driving
  Age    PEEP pressure SAPS
 Gender (years) BMI Comorbidities PaO2/FiO2 (cm H2O) (cm H2O) score
Patient 1 Female 53 32 Obesity 
    Hypertension 150 15  9 32
Patient 2  Male 63 33 Obesity 150 15  8 33
Patient 3 Male 59 29 Absent 180 14 10 29
Patient 4 Male 58 25 Rheumatoid arthritis  80 15 12 25
    Hypertension    
    Rectal cancer     
    (currently in     
    chemotherapy)    
Patient 5 Male 51 26 Absent 105 15 12 26
Patient 6 Male 49 26 Epilepsy  90 14 11 26
Patient 7 Female 50 24 Endometriosis 130 14 11 36
Patient 8 Male 50 27 Absent  70 14 11 28
Patient 9 Male 68 26 Hypertension
Legend: BMI, body mass index; DM, diabetes mellitus; PEEP, positive end-expiratory pressure; Driving Pressure = Plateau 
pressure – PEEP; SAPS, simplified acute physiology score.
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index of clinical suspicion. So, an appropriate 
treatment with anticoagulation can be initiated in 
a timely fashion. 
One of the hypotheses to explain a large dis-
crepancy between low hemodynamic alterations 
of PE and the radiological picture found in many 
of our patients may be a significant vasodila-
tion of pulmonary circulation. Indeed, Zhao et 
al19 showed that most patients with COVID-19 
pneumonia have a vascular enlargement of the 
pulmonary lesion that might have been caused by 
an acute inflammatory response. This would al-
low to not dramatically increase the resistance of 
the pulmonary circulation with consequent lower 
hemodynamic impact.
As shown in Table II, VTE diagnosis has been 
confirmed by CT scan with typical alterations 
for all patients except case 3 suffering sudden 
cardiac arrest. In this case diagnostic confirma-
tion was obtained performing transesophageal 
cardiac ultrasound during cardiopulmonary re-
suscitation. In the majority of patients, PaO2/FIO2 
markedly improved 48 hours after diagnosis and 
treatment of PE.
Our data confirms previous studies that de-
scribe thromboembolic events in patients with 
COVID-19 pneumonia5-7. Similar data can be 
found in other viral pulmonary infections like 
ARDS related to H1N120,21. In particular, Obi et 
al20 demonstrate a high incidence of VTE (44%) 
Table II. Clinical parameters of patients the day of diagnosis of thromboembolic event, diagnostic confirmation, treatment and outcome 48h 
after the diagnosis. 
Legend: VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; ICU, intensive care unit; P/F, PaO2/FiO2; DP, 
driving pressure; MAP, mean arterial pressure; NA, Noradrenaline; Dobut, Dobutamine; CT, computed tomography.
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in observational cohort study of 36 critically ill 
patients with H1N1 ARDS. In this study PE was 
described in 10 patients and DVT in other 10 
patients. Impressively this high rate of VTE was 
encountered despite antithrombotic prophylaxis. 
Cui et al7 recently showed that 25% of patients 
with severe COVID-19 pneumonia admitted to 
ICU developed lower extremity venous thrombo-
sis. The DVT group had older age, lower lympho-
cytes count, longer APTT and higher D-dimer. 
Table III. Lab test results related to the ICU patients’ admission, the day of diagnosis of thromboembolic event and 48 hours 
after the diagnosis. 
Legend: VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; ICU, intensive care unit; 
WBCs, white blood cells; Lymph, Lymphocytes; RCP, reactive C protein; PCT, procalcitonin; PLTS, platelets; PTT ratio, partial 
thromboplastin time; INR, international normalized ratio; ATIII, antithrombin III.
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Moreover, two recent case reports describe three 
patients with COVID-19 pneumonia complicated 
by acute pulmonary embolism confirmed by CT 
pulmonary angiography showing bilateral filling 
defects involving lobar, segmental, and subseg-
mental branches of the pulmonary artery5,6. Low-
er-limb compression ultrasonography was nega-
tive in one patient5 and was not reported in two 
other patients6.
The concept of pulmonary thrombosis has 
been recently proposed as clinical pathological 
entity distinct from pulmonary embolism22,23. Ac-
cording to this hypothesis coagulative response 
induced by COVID-19 may promote a local dis-
seminated intravascular coagulation and a pulmo-
nary intravascular thrombosis. This pathophysio-
logical mechanism may explain the presence of 
thrombotic material in pulmonary circulation in 
four of our patients, who did not show concomi-
tant evidence of DVT. Thus, in our view, patients 
affected by ARDS related to COVID-19 may de-
velop both pulmonary embolism and pulmonary 
thrombosis22, even though this hypothesis needs 
further investigation.
Conclusions
Critically ill patients with ARDS related to 
COVID-19 may have increased risk of VTE, dis-
seminated intravascular coagulation, pulmonary 
intravascular thrombosis and PE, which may rep-
resent a leading cause of mortality. Thus, these 
patients require a high index of clinical suspicion 
and an accurate diagnostic approach, in order to 
immediately start an appropriate anticoagulant 
treatment. Further studies are now needed to 
better understand the relationship between in-
creased thrombotic events and ARDS related to 
COVID-19.
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